Methylprednisolone in COVID-19 Patients (Methyl19LGH)
Status:
Recruiting
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
In COVID-19 deep airway and alveolar destruction occurred due to inflammatory reaction
resulting into severe pneumonia. In COVID-19, lung injury is not only due to viral damage to
tissue, but it is also due to immune response that leads to activation of inflammatory cells
and release of cytokines. In COVID-19 acute respiratory distress syndrome ARDS is produced
due to mucinous or cellular fibromyxoid exudates, desquamation of pneumocytes and alveolar
damage and hyaline membrane development and within 5-7 days disease become more aggressive
due to pneumonia and respiratory failure. It is important to start the prompt and strengthen
treatment for suppression of inflammatory response and cytokine storm. Methylprednisolone are
the traditional immunosuppressive drugs. They are important and effective to delay the
pneumonia progression and treating the ARDS.
Corticosteroids are broadly used as treatment for ARDS and there was an evidence for its
efficacy for treating SARS and decreasing mortality of SARS in the past. However for COVID-19
corticosteroids efficacy and safety usage is still under clinical trials